Business Highlights - BeiGene's Q1 2025 execution sets a strong foundation for the year, focusing on hematology franchise leadership, pipeline advancement, and superior financial performance[11] - Brukinsa is now the U S revenue leader among BTKis, with over 200,000 patients treated globally[17] - BeiGene has launched Brukinsa in Japan and it is now approved in 75 markets, with 11 new or expanded reimbursements including in Japan, EU, and Brazil[21] - Enrollment is complete in the Phase 3 CELESTIAL-TNCLL trial for Sonrotoclax, with global filing expected in R/R MCL in H2 2025[23] - BeiGene achieved GAAP profitability in Q1 2025, with GAAP Operating Income of $11 million compared to a loss of $261 million in Q1 2024[40] Financial Performance - Total revenue for Q1 2025 increased by 49% year-over-year, reaching $1.117 billion, compared to $752 million in Q1 2024[93, 95] - Net product revenue in Q1 2025 was $1.109 billion, a 48% increase from $747 million in Q1 2024[95, 96] - Brukinsa revenue in Q1 2025 reached $792 million, a 62% increase from $489 million in Q1 2024[95] - Tevimbra revenue in Q1 2025 was $171 million, an 18% increase from $145 million in Q1 2024[95] - GAAP earnings per ADS was $0.01 in Q1 2025, compared to a loss of $2.41 in Q1 2024[96]

Core Insights - The latest net value of ICBC Frontier Medical Stock A (001717) is 2.8300 yuan, reflecting a decrease of 1.77% [1] - The fund has shown a one-month return of 5.28%, ranking 400 out of 471 in its category; a three-month return of 8.06%, ranking 71 out of 471; and a year-to-date return of 7.56%, ranking 113 out of 469 [1] Fund Holdings - The top ten holdings of ICBC Frontier Medical Stock A account for a total of 59.05%, with the largest positions being: - Heng Rui Medicine (10.11%) - Kelun Pharmaceutical (8.01%) - WuXi AppTec (7.72%) - BeiGene (6.85%) - Xinlitai (4.90%) - Zai Lab (4.77%) - Yuyue Medical (4.60%) - New Horizon Health (4.36%) - East China Pharmaceutical (4.20%) - Haizhi Pharmaceutical (3.53%) [1] Fund Overview - ICBC Frontier Medical Stock A was established on February 3, 2016, and as of March 31, 2025, it has a total scale of 9.081 billion yuan [1] - The fund manager is Zhao Bei, who has extensive experience in the healthcare sector [2]

Core Viewpoint - BeiGene (06160) reported strong financial performance in Q1 2025, achieving revenue of 8.048 billion RMB, a year-on-year increase of 50.2%, driven by robust sales of its core products, Brukinsa® (Zebutinib) and Tislelizumab [1][2]. Financial Performance - The company transitioned from a loss to profit in both operating profit and total profit for Q1 2025, with significant improvement in operating cash flow [1]. - The full-year revenue guidance for 2025 remains unchanged, projected between 35.2 billion RMB and 38.1 billion RMB, supported by the anticipated strong growth of Brukinsa® in the U.S. and other key markets [1]. Product Performance - Brukinsa® achieved global sales of 5.692 billion RMB, a 63.7% increase year-on-year, with U.S. sales reaching 4.041 billion RMB, up 61.9% [2][3]. - In Europe, Brukinsa® sales were 836 million RMB, a 75.4% increase, while in China, sales reached 590 million RMB, a 43.1% increase [3]. Research and Development - The company is advancing its pipeline in hematologic malignancies, with the BCL2 inhibitor Sonrotoclax entering registration clinical trials and ongoing trials for various indications [3][4]. - BGB-16673, a BTK degrader, is in Phase 3 trials, expected to address BTK resistance issues [5]. PD-1 Product Development - Tislelizumab (替雷利珠单抗) generated sales of 1.245 billion RMB, a 19.3% increase, benefiting from new indications and increased hospital access [6]. - The product is approved in 46 markets globally, with over 1.5 million patients treated, and has recently gained reimbursement in 11 new markets [6]. Future Outlook - The company plans to host an investor R&D day on June 26, focusing on its breast cancer pipeline and broader oncology product portfolio [8]. - BeiGene will adopt a new English name, BeOne Medicines Ltd., and relocate its registration to Switzerland, expected to be completed later this year [8].

Group 1 - BeiGene reported a significant turnaround in its financial performance for Q1 2025, achieving total revenue of 8.048 billion yuan, a year-on-year increase of 50.2%, with product revenue reaching 7.985 billion yuan, up 49.9% [1] - The company transitioned from a loss to profitability, with a net profit attributable to the parent company of -94.503 million yuan, indicating a reduction in losses compared to the previous year, primarily driven by sales growth of self-developed products [1] Group 2 - Yuanjie Technology announced a sales order for high-power laser chip products amounting to 61.8716 million yuan, which is expected to positively impact the company's operating performance [2] Group 3 - Weide Information stated that it has not signed or is negotiating any significant contracts or new investment projects for industrial transformation, confirming normal operational conditions despite recent stock price fluctuations [3] Group 4 - Rishang Group received news that the U.S. Department of Commerce has revoked its investigation into steel wheels produced in Vietnam using Chinese components, which is expected to alleviate customer concerns and positively influence the company's export orders and future overseas business [4] Group 5 - Panga Micro透 announced plans for shareholders Sequoia Capital and Southern Precision to reduce their holdings by up to 7% of the company's total shares, with specific reductions of 2.8 million shares and 2.1 million shares respectively [5] Group 6 - Haohai Biology disclosed that its controlling shareholder, Jiang Wei, is under investigation for insider trading, although this matter is unrelated to the company's daily operations and is not expected to have a significant impact on the company [6] Group 7 - Qingdao Beer plans to acquire 100% equity of Jimo Yellow Wine for a total consideration of 666 million yuan, aiming to enhance industry synergy, competitiveness, and product diversification [7] Group 8 - Yonggui Electric announced that independent director Liu Jian has been detained by relevant supervisory authorities, but this matter does not pertain to the company, and other board members continue to perform their duties normally [8] Group 9 - Zhongchao Holdings reported that during a period of stock price volatility, its actual controller sold 0.11% of the company's shares, amounting to 1.53 million shares, while confirming that no shares were bought or sold by the controlling shareholder during this period [9] Group 10 - Changshan Pharmaceutical stated that its injection product, Aibennate, has not yet been launched for sale, and while the application for market approval is under review, there remains uncertainty regarding its approval and market competition [10] Group 11 - Zhi Yuan New Energy plans to repurchase between 1.5 million and 3 million shares of its stock, while Keda Guochuang has secured a commitment for a stock repurchase loan of up to 36 million yuan [11] - Xinya Technology's actual controller and major shareholder plan to reduce their holdings by a total of 327,000 shares [11] Group 12 - Jinguang Co. recently won bids for projects totaling 258 million yuan, while Zongheng Co.'s subsidiary secured a 106 million yuan project for a low-altitude digital economy unmanned system and supporting facilities [12]

美国证券交易委员会 百济神州有限公司 （注册人章程中载明的准确名称） Washington, D.C. 20549 ___________________________________________________________ 表格 10-Q ___________________________________________________________ （选择一项） ☒ 根据 1934 年证券交易法第 13 条或第 15（d）条编制的季度报告 截至 2025 年 3 月 31 日的季度期间 或 ☐ 根据 1934 年证券交易法第 13 条或第 15（d）条编制的过渡报告 过渡期从 至 交易委员会档案编号：001-37686 开曼群岛 98-1209416 （注册成立或组织所在的州或其他司法管辖区） （美国国家税务局雇主身份识别号码） c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman （主要行政办事处地址） （邮政编码） 开曼群岛 KY1-1108 +1 (345 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeiGene, Ltd. 百濟神州有限公司 （於開曼群島註冊成立的有限公司） （股份代號：06160） 內幕消息 百濟神州有限公司 截至2025年3月31日止三個月未經審核業績以及 業務進展最新情況 本公告乃根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及 根據證券及期貨條例（香港法例第571章）第XIVA部而刊發。 百濟神州有限公司（「本公司」或「百濟神州」）欣然公佈其截至2025年3月31日止 三個月的未經審核簡要合併財務業績以及業務進展最新情況。 本公司欣然公佈本公司及其附屬公司截至2025年3月31日止三個月未經審核簡要 合併財務業績（「第一季度業績」）以及2025年第一季度關鍵業務亮點和重申2025年 年度財務指引（「業務進展」）。第一季度業績乃根據美國證券交易委員會的適用規 則刊發。 第一季度業績乃根據美國公認會計準則編製，而美國公認會計準則有別於國際財 務報告準則。 ...

A 股代码：688235 A 股简称：百济神州 公告编号：2025-021 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025年第一季度主要财务数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）2025 年第一季度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公 司 2025 年第一季度报告中披露的数据为准，提请投资者注意投资风险。 本公告财务数据按中国企业会计准则编制并呈列。 本公司已于 2025 年 5 月 7 日同步发布了根据美国公认会计原则及美国证券交 易委员会适用规则编制的截至 2025 年 3 月 31 日止第一季度未经审计财务业绩，提 请投资者注意与本公告区别。 1 一、2025 年第一季度主要财务数据和指标 R/R MZL和R/R FL；获得中国国家药品监督管理局（NMPA）批准用于治疗CLL/SLL、 WM、R/R MCL和R/R FL。百悦泽®是目前分别在美国和中国获批适应 ...

Core Viewpoint - BeiGene reported a 50.2% increase in Q1 2025 revenue to 8.048 billion yuan, with a net loss of 94.503 million yuan, driven by strong sales of its self-developed products [1][2]. Revenue Growth - Q1 product revenue reached 7.985 billion yuan, up 49.9% year-on-year, primarily due to the sales growth of the self-developed drug Brukinsa® (Zebutinib) and the sales of Tislelizumab and Amgen licensed products [1]. - Global sales of Brukinsa® totaled 5.692 billion yuan in Q1, a 63.7% increase year-on-year, solidifying its leadership in the hematologic oncology field [1][2]. - Sales in the U.S. amounted to 4.041 billion yuan, reflecting a 61.9% year-on-year growth, driven by increased demand, particularly in chronic lymphocytic leukemia (CLL) indications [1]. - European sales reached 836 million yuan, up 75.4% year-on-year, attributed to market share gains across major European markets [1]. Market Position - In China, sales totaled 590 million yuan, a 43.1% increase year-on-year, maintaining a leading market share in the BTK inhibitor market [2]. - Brukinsa® has been included in the National Medical Insurance Directory for all four approved indications in China [2]. - Sales of Tislelizumab reached 1.245 billion yuan in Q1, a 19.3% increase year-on-year, driven by new indications covered by insurance and increased hospital access [2]. Clinical Development - Brukinsa® is the only BTK inhibitor with the most extensive approved indications globally and offers flexible dosing options [2]. - The clinical development program for Brukinsa® has been conducted in over 30 countries with more than 35 trials involving approximately 7,100 patients [2]. - The global Phase III ALPINE trial demonstrated sustained progression-free survival (PFS) benefits for Brukinsa® compared to ibrutinib in treating relapsed or refractory CLL/SLL patients [3]. - The company continues to advance key research projects, including the global clinical trials for Sonrotoclax, a BCL2 inhibitor, in combination with Brukinsa® for CLL and other indications [3].

Core Insights - The company reported a total revenue of 8.048 billion yuan in Q1 2025, representing a year-on-year increase of 50.2% [1] - Product revenue reached 7.985 billion yuan, with a year-on-year growth of 49.9% [1] - The company achieved an operating profit of 151 million yuan, a significant improvement from a loss of 1.83 billion yuan in the same period last year [1] - The net loss attributable to the parent company was 94.503 million yuan, compared to a loss of 1.908 billion yuan in the previous year [1] - The growth in product revenue was primarily driven by increased sales of self-developed products Baiyueze® and Baizean® [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of BeiGene, a global biotechnology company focused on innovative drug development and commercialization [1][2] - As of May 7, BeiGene's stock closed at 238.5 yuan, down 7.92%, with a market-to-book ratio of 13.84 and a total market capitalization of 334.535 billion yuan [1] - The latest financial report for the year 2024 shows that BeiGene achieved a revenue of 27.214 billion yuan, representing a year-on-year increase of 56.19%, while the net profit was -4.978287 million yuan, a year-on-year decline of 25.87%, with a gross margin of 84.44% [1] Group 2 - As of March 31, 2025, BeiGene had 24,071 shareholders, a decrease of 7,486 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - In comparison to industry averages, BeiGene's price-to-earnings (P/E) ratio (TTM) is -67.20, while the industry average is 57.27, indicating a significant divergence in valuation metrics [2] - The industry median P/E ratio is 38.99, while BeiGene's market capitalization stands at 334.535 billion yuan, positioning it among the larger companies in the biotechnology sector [2]